Buscar
Alpha Cognition Inc
ACOGAñadir a la lista de seguimiento
8.280USD
-0.450-5.15%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
180.29MCap. mercado
PérdidaP/E TTM
Más Datos de Alpha Cognition Inc Compañía
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
Información de Alpha Cognition Inc
Símbolo de cotizaciónACOG
Nombre de la empresaAlpha Cognition Inc
Fecha de salida a bolsaJun 09, 2021
Director ejecutivoMcfadden (Michael E)
Número de empleados52
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 09
Direcciónc/o 1200 - 750 West Pender Street
CiudadVANCOUVER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV6C 2T8
Teléfono16045649244
Sitio Webhttps://www.alphacognition.com/
Símbolo de cotizaciónACOG
Fecha de salida a bolsaJun 09, 2021
Director ejecutivoMcfadden (Michael E)
Ejecutivos de Alpha Cognition Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael E Mcfadden
Mr. Michael E Mcfadden
Chief Executive Officer, Director
Chief Executive Officer, Director
204.69K
--
Mr. Kenneth A. (Ken) Cawkell
Mr. Kenneth A. (Ken) Cawkell
Corporate Secretary, Director
Corporate Secretary, Director
--
--
Mr. Rajeev (Rob) Bakshi
Mr. Rajeev (Rob) Bakshi
Independent Director
Independent Director
--
--
Mr. Len Mertz
Mr. Len Mertz
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. John Havens
Mr. John Havens
Independent Director
Independent Director
--
--
Mr. Phillip Mertz
Mr. Phillip Mertz
Independent Director
Independent Director
--
--
Ms. Lauren D'Angelo
Ms. Lauren D'Angelo
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Henry Du
Mr. Henry Du
Interim Chief Financial Officer, Vice President - Finance and Accounting
Interim Chief Financial Officer, Vice President - Finance and Accounting
--
--
Dr. Robert Wills
Dr. Robert Wills
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael E Mcfadden
Mr. Michael E Mcfadden
Chief Executive Officer, Director
Chief Executive Officer, Director
204.69K
--
Mr. Kenneth A. (Ken) Cawkell
Mr. Kenneth A. (Ken) Cawkell
Corporate Secretary, Director
Corporate Secretary, Director
--
--
Mr. Rajeev (Rob) Bakshi
Mr. Rajeev (Rob) Bakshi
Independent Director
Independent Director
--
--
Mr. Len Mertz
Mr. Len Mertz
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. John Havens
Mr. John Havens
Independent Director
Independent Director
--
--
Mr. Phillip Mertz
Mr. Phillip Mertz
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Alpha Cognition Inc?
Los cinco principales accionistas de Alpha Cognition Inc son: Mr. Michael E Mcfadden
¿Cuántas instituciones poseen acciones de Alpha Cognition Inc (ACOG)?
A fecha de 2026Q1, 51 instituciones poseen acciones de Alpha Cognition Inc, con un valor de mercado combinado de aproximadamente 11.46M, lo que representa el 52.64% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1538079.00.